Related Experiment Videos
Calcium antagonists during and after myocardial infarction
1John Radcliffe Hospital, University of Oxford, England.
Drugs
|February 1, 1996
Summary
Calcium channel blockers show varied effects in acute myocardial infarction (AMI). Non-dihydropyridines like verapamil reduce mortality, while short-acting dihydropyridines such as nifedipine may increase harm.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Calcium antagonists (calcium channel blockers) were proposed as cardioprotective agents for acute myocardial infarction (AMI) based on animal studies.
- Animal models suggested these agents could mitigate calcium overload during ischemia and reperfusion and reduce coronary artery spasm.
- However, clinical data on mortality benefits in AMI patients remained unclear.
Purpose of the Study:
- To evaluate the efficacy and safety of different classes of calcium antagonists in patients with acute myocardial infarction (AMI).
- To differentiate the clinical outcomes associated with dihydropyridine and non-dihydropyridine calcium antagonists in AMI and post-MI prophylaxis.
- To assess the impact of calcium antagonists on mortality, reinfarction, and sudden death in AMI patients.
Main Methods:
- An overview of data from multiple randomized controlled clinical trials involving calcium antagonists in AMI.
- Comparison of outcomes between dihydropyridine (e.g., nifedipine) and non-dihydropyridine (verapamil, diltiazem) calcium antagonists.
- Analysis of specific trial data, including TRENT, HINT, SPRINT-I/II for nifedipine, and DAVIT-I/II for verapamil.
Main Results:
- Short-acting dihydropyridine nifedipine trials showed no significant benefit and a trend towards harm, with one trial stopped early due to increased reinfarction.
- Combined data from DAVIT-I and DAVIT-II demonstrated significant reductions in sudden death, reinfarction, and total mortality with verapamil.
- Verapamil showed the greatest benefit in patients with preserved left ventricular function; similar, less significant trends were observed with diltiazem.
Conclusions:
- Calcium antagonists are not a homogeneous class in AMI management; outcomes differ significantly between dihydropyridines and non-dihydropyridines.
- Adverse effects of nifedipine may stem from reflex sympathetic stimulation due to its vasodilatory action.
- Beta-blockers or verapamil are recommended as proven agents for AMI, pending data on newer dihydropyridines.